Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR2 | O43614 | 2/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA7 | P43166 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | CTSL | P07711 | 1/20 | 0.34 |
| ▸ | CTSK | P43235 | 4/20 | 0.33 |
| ▸ | CTSS | P25774 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.32 |
| ▸ | PREP | P48147 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13725768 | 0.82 | HCRTR2 (0.40) | HCRTR2CA1CA2CA7CYP2D6 | |
| SCHEMBL28588817 | 0.82 | HCRTR2 (0.40) | HCRTR2CA1CA2CA7CYP2D6 | |
| SCHEMBL28580334 | 0.81 | HCRTR2 (0.39) | HCRTR2CA1CA2CA7CYP2D6 | |
| SCHEMBL28580336 | 0.81 | HCRTR2 (0.39) | HCRTR2CA1CA2CA7CYP2D6 | |
| SCHEMBL18681520 | 0.80 | CA1 (0.45) | HCRTR2CA1CA2CA7CYP2D6 | |
| SCHEMBL590366 | 0.80 | CA1 (0.45) | HCRTR2CA1CA2CA7CYP2D6 | |
| SCHEMBL15627222 | 0.80 | CA1 (0.45) | HCRTR2CA1CA2CA7CYP2D6 | |
| SCHEMBL14357347 | 0.80 | CA1 (0.45) | HCRTR2CA1CA2CA7CYP2D6 | |
| SCHEMBL3182760 | 0.79 | HCRTR2 (0.34) | HCRTR2CA2HCRTR1 | |
| SCHEMBL14163608 | 0.77 | HCRTR2 (0.45) | HCRTR2KMT2AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010007427-A1 | PYRIMIDYL SULFONAMINDE DERIVATIVE AND ITS USE FOR THE TREATMENT OF CHEMOKINE MEDIATED DISEASES | ASTRAZENECA AB (SE) | 2010-01-21 | — | — | WO | disclosed |
| US-20100016275-A1 | NOVEL COMPOUND 395 | ASTRAZENECA AB (SE) | 2010-01-21 | — | — | US | disclosed |
| US-20100016275-A1 | NOVEL COMPOUND 395 | ASTRAZENECA AB (SE) | 2010-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016275-A1 | NOVEL COMPOUND 395 | CCL5, CCL2, CCL11 | HCRTR2 2344/4885CA1 4362/4885CA2 4510/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.